PMID- 36318461
OWN - NLM
STAT- MEDLINE
DCOM- 20221103
LR  - 20230307
IS  - 1557-2501 (Electronic)
IS  - 1042-3931 (Linking)
VI  - 34
IP  - 11
DP  - 2022 Nov
TI  - Procedural Performance of Ultrathin, Biodegradable Polymer-Coated Stents Versus 
      Durable Polymer-Coated Stents Based on Intracoronary Imaging.
PG  - E811-E819
AB  - OBJECTIVE: Thinner stent struts might lead to a higher risk of recoil and 
      subsequently a smaller minimal stent area (MSA), which is known to be the 
      strongest predictor of stent failure. We compared procedural performance between 
      an ultrathin-strut biodegradable-polymer sirolimus-eluting stent (BP-SES) and a 
      durable-polymer zotarolimus-eluting stent (DP-ZES) using intracoronary imaging. 
      METHODS: A consecutive cohort of patients underwent percutaneous coronary 
      intervention (PCI) with either BP-SES or DP-ZES in a pseudorandomized fashion 
      between July 2018 and October 2019. In the present subanalysis, we included cases 
      in which post-PCI imaging with intravascular ultrasound (IVUS) or optical 
      coherence tomography (OCT) was performed. The primary endpoint of the study was 
      MSA. Secondary endpoints included percentage stent expansion and presence of 
      residual edge disease, malapposition, tissue protrusion, submedial edge 
      dissections, or edge hematoma. RESULTS: A total of 141 treated lesions (78 BP-SES 
      and 63 DP-ZES) in 127 patients were analyzed. Median age was 69.3 years 
      (interquartile range [IQR], 57.3-75.6) and 74.0% of patients were male. All 
      baseline and procedural characteristics were comparable between both groups. 
      Median MSA was 5.80 mm(2) (IQR, 4.40-7.24) for BP-SES and 6.35 mm(2) (IQR, 4.76-8.31) 
      for DP-ZES (P=.15). No significant differences in stent expansion, residual edge 
      disease and presence of malapposition, tissue protrusion, submedial edge 
      dissections, or edge hematomas were found. Stent diameter and stent length were 
      found to be independent predictors of MSA. CONCLUSIONS: No significant 
      differences in MSA were found between lesions treated with BP-SES vs DP-ZES. 
      BP-SES and DP-ZES were comparable in terms of procedural performance.
FAU - Ziedses des Plantes, Annemieke C
AU  - Ziedses des Plantes AC
FAU - Neleman, Tara
AU  - Neleman T
FAU - Tovar Forero, Maria N
AU  - Tovar Forero MN
FAU - Visser, Leon
AU  - Visser L
FAU - Scoccia, Alessandra
AU  - Scoccia A
FAU - Groenland, Frederik T W
AU  - Groenland FTW
FAU - Ligthart, Jurgen M R
AU  - Ligthart JMR
FAU - Boersma, Eric
AU  - Boersma E
FAU - Nuis, Rutger-Jan
AU  - Nuis RJ
FAU - den Dekker, Wijnand K
AU  - den Dekker WK
FAU - Wilschut, Jeroen
AU  - Wilschut J
FAU - Diletti, Roberto
AU  - Diletti R
FAU - Zijlstra, Felix
AU  - Zijlstra F
FAU - Van Mieghem, Nicolas M
AU  - Van Mieghem NM
FAU - Daemen, Joost
AU  - Daemen J
AD  - Department of Cardiology, Room Rg-628, Erasmus University Medical Center, P.O. 
      Box 2040, 3000 CA Rotterdam, The Netherlands. j.daemen@erasmusmc.nl.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
RN  - 9HW64Q8G6G (Everolimus)
RN  - 0 (Polymers)
RN  - 0 (Cardiovascular Agents)
RN  - H4GXR80IZE (zotarolimus)
SB  - IM
MH  - Humans
MH  - Male
MH  - Aged
MH  - Female
MH  - *Drug-Eluting Stents
MH  - *Percutaneous Coronary Intervention
MH  - Everolimus
MH  - Absorbable Implants
MH  - Polymers
MH  - *Cardiovascular Agents
MH  - *Coronary Artery Disease/therapy
MH  - Prosthesis Design
MH  - Treatment Outcome
OTO - NOTNLM
OT  - drug-eluting stents
OT  - intravascular ultrasound
OT  - optical coherence tomography
OT  - percutaneous coronary intervention
EDAT- 2022/11/02 06:00
MHDA- 2022/11/04 06:00
CRDT- 2022/11/01 12:32
PHST- 2022/11/01 12:32 [entrez]
PHST- 2022/11/02 06:00 [pubmed]
PHST- 2022/11/04 06:00 [medline]
PST - ppublish
SO  - J Invasive Cardiol. 2022 Nov;34(11):E811-E819.